Group 1 - The 2025 China Public Welfare Charity Project Exchange and Exhibition will be held in Guangzhou from December 12 to 13, focusing on children's health initiatives [1] - JD Health hosted a seminar titled "Professional Empowerment: Enhancing Charitable Efforts in Children's Health," guided by the China Charity Federation, with over a hundred experts and practitioners in attendance [1] - The Vice President of the China Charity Federation emphasized the importance of children's mental and physical health in building a healthy China and highlighted the unique advantages of charitable efforts in supporting high-risk groups such as left-behind and migrant children [1] Group 2 - JD Health's Internet Medical Business leader stated that the company prioritizes the protection of children's health, leveraging its professional capabilities and internet platform to create a comprehensive support system covering prevention, assessment, and intervention [2] - JD Health has introduced innovative practices in children's mental health, including AI psychological assessments and digital companionship, as well as a closed-loop service model combining online screening and offline graded intervention [2] - The company shared multiple initiatives in the field of children's mental health, such as supporting the CAFF Garden project for families of patients with severe mental disorders and collaborating on the "Child Heart Growth" project to provide psychological resources for left-behind and migrant children [2]

Core Insights - The conference themed "A New Chapter, Building the Future" highlighted the future trends of pharmaceutical instant retail and explored new paths for high-quality growth [1] - JD Health emphasized the importance of a user, supply chain, and logistics-centric ecosystem for instant retail, introducing a growth triangle model focused on supply, experience, and users [1] Group 1: Market Trends - Instant retail has become the main growth engine for the pharmaceutical health sector, driven by the rising health consciousness among younger consumers [2] - JD Health reported a 16% year-on-year increase in the proportion of users under 30 for its instant delivery service, with student users increasing by 11.5% year-on-year [2] - The market for instant retail is projected to exceed 1 trillion yuan by 2025, growing at a rate of 29%, and surpass 2 trillion yuan by 2030 [2] Group 2: Capability Building - JD Health is building a "super pharmaceutical supply chain" as the foundation for its instant retail capabilities, focusing on a growth triangle model of supply, experience, and users [3] - The supply side has achieved nationwide coverage with a network spanning over 2,600 counties and cities, supported by over 200,000 delivery personnel, enabling delivery in as fast as 9 minutes [3] - Since April 2025, the number of JD Health's instant delivery pharmacies has increased by over 100% year-on-year, with order volume growing over 200% [3] Group 3: User Engagement - JD Health leverages its base of over 600 million active users to enhance channel operations and search recommendation mechanisms, transitioning from "people finding medicine" to "medicine finding people" [4] - The company provides scenario-based marketing solutions aligned with seasonal diseases and major promotional events to improve user engagement and conversion rates [4] Group 4: Collaborative Growth - JD Health's collaboration with partners has demonstrated significant results, such as reducing inventory turnover days for partners like Hongyu Pharmaceutical through access to JD Health's instant delivery network [5] - The Asia-Pacific region is identified as a growth engine for the self-care market, with strong consumer demand in pain management and allergy relief [5] - Looking ahead to 2026, JD Health plans to focus on specialization in instant retail and will open up data capabilities, traffic resources, and operational tools to partners [5]

来源：第一财经 恒生指数低开1%，恒生科技指数跌1.34%。京东健康跌逾5%，百度集团跌逾3%，理想汽车、阿里巴巴 跌逾2%。 (本文来自第一财经) ...

Core Viewpoint - JD Health is advancing its medical AI capabilities through the "Jingyi Qianxun" model, focusing on specialized disease models for cancer treatment and chronic diseases, collaborating with top medical institutions in China to enhance clinical practices and patient management [1][3][4]. Group 1: Technological Advancements - JD Health's "Jingyi Qianxun" medical AI model has evolved from a general model to specialized disease models, demonstrating significant technological progress since 2018 [4]. - The model integrates high-quality clinical data from JD's online healthcare services and collaborates with national medical data centers to optimize its foundational model [4][5]. - The specialized disease models are developed using real-world clinical data, ensuring alignment with actual clinical needs and incorporating insights from over 1,000 experts across more than 400 top-tier hospitals [5][6]. Group 2: Collaborative Initiatives - JD Health, in partnership with the China Anti-Cancer Association, launched the "Cancer Integration Prevention and Treatment Project (2025-2030)" to create a comprehensive cancer prevention and treatment system [3]. - Collaborations with leading hospitals, such as Peking University Cancer Hospital and Sun Yat-sen University Cancer Center, focus on developing specialized models for various cancer types, including gastrointestinal and respiratory cancers [5][6]. Group 3: AI Integration in Clinical Practice - The AI-driven tools, such as the AI doctor assistant, have improved the efficiency of oncologists, achieving over 90% resolution of repetitive queries and enhancing diagnostic processes by more than 50% [8]. - JD Health's research platform utilizes AI to streamline data collection and patient follow-up, significantly improving research efficiency and data quality for ongoing studies [8]. Group 4: Future Directions - JD Health aims to enhance its medical AI model towards human-like clinical cognition and will continue to foster open collaborations with medical institutions and experts [9]. - The company is committed to building a specialized cancer prevention and treatment system that ensures accessible resources, reliable decision-making, and effective patient management, contributing to the "Healthy China 2030" initiative [9].

针对肿瘤科普内容真伪难辨、大众对肿瘤早筛重视不足等痛点，京东健康与中国抗癌协会将推出肿瘤防 治科普行动；围绕医疗资源均衡可及、基层医院专科建设等需求，双方将推出肿瘤医生赋能计划；此 外，双方还将开展肿瘤康复技术产学研合作。 在肿瘤专科建设及专病防治方面，依然存在医疗资源分布不均、临床决策复杂、科研转化滞后、患者管 理低效等系统性挑战。 京东健康医疗及AI应用平台部负责人表示，京东健康依托京医千询大模型，全面加速"医检诊药"闭环， 打造AI京医专业服务智能体、专家医生智能体、RWD科研平台，以医疗级AI为目标，形成资源可及、 决策可依、科研可转化、患者可管理的智能肿瘤防治体系，为医生赋能、为患者服务、为行业提效。 数据显示，我国每年新发癌症病例数超400万例，近10年来，患者5年生存率从33.3%上升至43.7%，但 谈癌色变、无症状不做肿瘤筛查、治胜于防等认知误区仍然存在。 大会前一日，樊代明院士专程率团队到访京东总部，与京东集团SEC委员、京东健康CEO曹冬和相关业 务团队进行了深入交流。双方围绕"肿瘤整合防治工程（2025-2030）"的推进路径展开务实探讨，樊院 士对京东健康在推动肿瘤防治体系化、数字化 ...

本报讯 （记者梁傲男）12月13日，由中国抗癌协会与京东健康共同发起的肿瘤整合防治工程正式启 动，同期，2025肿瘤防治新进展大会在京举行。 大会汇聚由中国工程院院士、中国抗癌协会理事长樊代明领衔的顶尖专家阵容，聚焦肿瘤领域学术新进 展、医工交叉新技术、专病大模型及科研成果转化等前沿和热点议题，打造了一场肿瘤防治的学术盛 宴。 京 东供图 在肿瘤专科建设及专病防治方面，依然存在医疗资源分布不均、临床决策复杂、科研转化滞后、患者管 理低效等系统性挑战。 京东健康医疗及AI应用平台部负责人表示，京东健康依托京医千询大模型，全面加速"医检诊药"闭环， 打造AI京医专业服务智能体、专家医生智能体、RWD科研平台，以医疗级AI为目标，形成资源可及、 决策可依、科研可转化、患者可管理的智能肿瘤防治体系，为医生赋能、为患者服务、为行业提效。 京东集团SEC委员、京东健康CEO曹冬表示，作为中国肿瘤防治事业的参与者和推动者，京东健康始终 坚持"以专业守护生命"的理念，携手中国抗癌协会等权威机构，系统推进从科普教育、早筛早诊到规范 诊疗、康复管理的全程服务，切实守护大众健康。未来，京东健康将持续与各方合作伙伴并肩，深化人 工智 ...

目前，京东互联网医院肿瘤专科已全面升级，通过权威三甲医院专家团队与AI智能技术结合，构建"筛 查、诊断、治疗、随访"一体化服务体系。据悉，该肿瘤专科已有3万余名三甲医院权威专家。 会上，京东健康分别与广州医科大学附属第一医院、中山大学孙逸仙纪念医院、北京大学肿瘤医院进行 AI专病课题合作签约。聚焦消化道肿瘤、前列腺癌及呼吸系统等方向，京东健康将基于京医千询大模 型技术能力，携手三大医疗机构围绕AI在影像识别、病情动态监测与辅助诊疗等方面的创新应用与前 沿进展进行深度合作。 新浪科技讯 12月14日上午消息，昨日，在2025肿瘤防治新进展大会上，京东健康与中国抗癌协会共同 发起"肿瘤整合防治工程（2025-2030）"，构建"防-筛-诊-治-康"全流程体系，将AI等前沿技术深度融合 于临床实践，探索肿瘤防治的中国路径。 针对肿瘤科普内容真伪难辨、大众对肿瘤早筛重视不足等痛点，京东健康与中国抗癌协会将推出肿瘤防 治科普行动；围绕医疗资源均衡可及、基层医院专科建设等需求，双方将推出肿瘤医生赋能计划；此 外，双方还将开展肿瘤康复技术产学研合作。 京东健康医疗及AI应用平台部负责人表示，京东健康依托京医千询大模型，全面 ...

Group 1 - The core point of the news is that southbound funds have significantly reduced their holdings in JD Health, with a total net reduction of 704.93 million shares over the last five trading days and 1,253.46 million shares over the last 20 trading days [1] - As of now, southbound funds hold 267 million shares of JD Health, which accounts for 8.32% of the company's total issued ordinary shares [1] Group 2 - JD Health is primarily an investment holding company that provides pharmaceutical and health products, internet medical health services, health management, and smart medical health solutions [2] - The company's business includes retail pharmacy and medical health services, with retail pharmacy operations conducted through self-operated and online platforms as well as instant retail channels [2] - Medical health services are mainly provided through internet hospitals and medical large models, and the company also offers online marketing services such as advertising [2]

Group 1 - The core viewpoint of the article highlights the approval of Novartis' innovative drug, Noreda® (Acrylamide Hydrochloride Tablets), as the first non-immunosuppressive therapy for IgA nephropathy in China, addressing a significant treatment gap in this area [1][3] - IgA nephropathy is prevalent among young adults in China, particularly those aged 20 to 30, with a high risk of progression to kidney failure if not effectively managed [1] - The drug is expected to be used in conjunction with existing standard treatments, providing new options for long-term disease management for patients [1][3] Group 2 - JD Health will leverage its robust pharmaceutical health service ecosystem to deepen its focus on chronic disease management, particularly in kidney diseases [1] - The collaboration with a leading global pharmaceutical company like Novartis aims to introduce cutting-edge therapeutic drugs and comprehensive digital health management solutions for patients [1][3] - JD Health's capabilities in supply chain fulfillment and professional pharmacist services will enhance the accessibility and precision of innovative drugs reaching patients nationwide [3]

Core Insights - Novartis has launched its innovative drug, Noreda (Acrylamide Hydrochloride Tablets), on JD Health, marking it as the first approved non-immunological therapy for adult patients with primary IgA nephropathy in China [1][2] - The drug is a highly selective endothelin A (ETA) receptor antagonist, filling a significant gap in non-hormonal basic treatments for this condition [2] Group 1 - Noreda is designed to reduce the risk of rapid disease progression in IgA nephropathy patients, which is prevalent among young adults aged 20 to 30 in China [1] - Clinical studies indicate that approximately 50% of IgA nephropathy patients with persistent proteinuria may progress to renal failure within 10 to 20 years if not effectively managed [1] - The collaboration between JD Health and Novartis aims to enhance the accessibility and precision of innovative treatments for patients nationwide [1][2] Group 2 - JD Health plans to deepen its focus on chronic disease management, particularly in kidney diseases, by leveraging its robust healthcare service ecosystem [2] - The introduction of Noreda is expected to provide new options for long-term disease management alongside existing standard treatments [2] - JD Health aims to offer comprehensive digital health management solutions for patients, improving the quality of life for those with kidney diseases and other chronic conditions [2]